Amarin Corp Plc (AMRN)

[antibluechip]

Capt: Is that ESC-2023 ad lacking the most important fact about Vascepa, The PERCENTAGE of RISK REDUCTION by adding it to a statin. Or am I missing something? I see the words "the proven efficacy of VASCEPA/VAZKEPA in cardiovascular risk reduction," but nowhere do I see the NUMBER, 25 or 30 percent risk reduction OVER a statin.. I keep harping on this because that has to be the single most important fact that practitioners and patients need to be informed about. It should be "front and center" on every ad and publication of Amarin.